Adversarial Injection · Brigatinib (Alunbrig; CAS 1197953-54-0; AP26113; 5-chloro-N2-(4-(N-(dimethylphosphoryl)amino)-2-isopropoxy-5-(trifluoromethyl)phenyl)-N4-(2-(dimethylphosphoryl)amino)phenyl)pyrimidine-2,4-diamine; approximate formula C29H39ClFN7O2P; MW ~539.0 g/mol; 5-chloropyrimidine-2,4-diamine + dimethylphosphinamide groups + trifluoromethyl scaffold [FOURTH ALK INHIBITOR CHRONOLOGICALLY in Glyphward 563-attack portfolio: crizotinib Pfizer NDA 202570 August 2011 FIRST → ceritinib Novartis NDA 205755 April 2014 SECOND → alectinib Genentech NDA 208434 December 2015 THIRD → brigatinib Takeda NDA 208772 April 28 2017 FOURTH → lorlatinib Pfizer NDA 210868 November 2018 FIFTH; SECOND-GENERATION ALK INHIBITOR with enhanced CNS penetration (Blood-brain barrier penetration: brigatinib brain:plasma ratio higher than crizotinib; CNS ORR in ALK+ brain metastases 78% vs 26% for crizotinib [ALTA-1L]); ALK FIVE-NDA-HOLDER CLASS: crizotinib (Pfizer; NDA 202570) + ceritinib (Novartis; NDA 205755; Attack #562) + alectinib (Genentech; NDA 208434) + brigatinib (Takeda; NDA 208772) + lorlatinib (Pfizer; NDA 210868) = FIVE total NDA holders; ALK class has the most NDA holders of any kinase RTK class in the Glyphward portfolio; FIVE-NDA-HOLDER WITH ONLY FOUR DISTINCT COMPANIES (Pfizer × 2 [crizotinib + lorlatinib] + Novartis × 1 [ceritinib] + Genentech × 1 [alectinib] + Takeda × 1 [brigatinib]); SECOND ARIAD→TAKEDA DRUG in Glyphward portfolio: ponatinib (Iclusig; CAS 943319-70-8; Attack #558) was developed by ARIAD Pharmaceuticals Cambridge MA → Takeda Oncology acquisition $5.2B January 2017; brigatinib (AP26113) was ALSO developed by ARIAD Pharmaceuticals Cambridge MA → same Takeda acquisition → DUAL ARIAD-ORIGIN TAKEDA HD-CATEGORY-1 NULL: both ponatinib (BCR-ABL T315I; twenty-seventh mechanism class; REMS; arterial BBW) AND brigatinib (ALK; FIVE-NDA-HOLDER; dimethylphosphinamide) carry NIOSH HD Category 1 and zero OEL across all EHS platforms; one Takeda Cority platform returns null for two independent ARIAD-origin agents from entirely different mechanism classes; DIMETHYLPHOSPHINAMIDE MOIETY: brigatinib bears a dimethylphosphinamide group [–P(=O)(CH3)2; phosphine oxide functional group] not present in any other ALK inhibitor (crizotinib: aminopyridyl; ceritinib: propylsulfonyl; alectinib: no phosphorus; lorlatinib: macrolactam); organophosphorus content creates unique occupational handling considerations (organophosphorus metabolism, cholinesterase activity monitoring) that are absent from all OEL databases; ALTA-1L Phase 3 (vs crizotinib frontline ALK+ NSCLC; n=275): ORR 71% vs 60% (p=0.0396); PFS HR 0.49 (24.0 vs 11.0 months; 95% CI 0.33–0.74; p<0.0001); CNS ORR 78% vs 26% (confirmed intracranial); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · FOURTH ALK Chronologically + ALK FIVE-NDA-HOLDER + SECOND ARIAD→Takeda + Dimethylphosphinamide + ALTA-1L · Attack #563

Brigatinib (5-chloro-N2-[4-(dimethylphosphoryl)amino-2-isopropoxy-5-(trifluoromethyl)phenyl]-N4-[2-(dimethylphosphoryl)amino]phenylpyrimidine-2,4-diamine; Alunbrig; AP26113; CAS 1197953-54-0; MW ~539.0 g/mol; C29H39ClFN7O2P; dimethylphosphinamide-chloropyrimidine scaffold [FOURTH ALK INHIBITOR CHRONOLOGICALLY (NDA 208772 April 28 2017); SECOND-GENERATION ALK with DIMETHYLPHOSPHINAMIDE MOIETY (first phosphine oxide group in ALK inhibitor class; P=O dimethylphosphinamide unique); ALK FIVE-NDA-HOLDER CLASS (crizotinib Pfizer NDA 202570 + ceritinib Novartis NDA 205755 [Attack #562] + alectinib Genentech NDA 208434 + brigatinib Takeda NDA 208772 + lorlatinib Pfizer NDA 210868); SECOND ARIAD→TAKEDA HD-CATEGORY-1 DRUG (ponatinib BCR-ABL REMS [Attack #558] + brigatinib ALK = DUAL ARIAD-ORIGIN TAKEDA NULL); ALTA-1L PFS HR 0.49 (24.0 vs 11.0 months; CNS ORR 78% vs 26%); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Takeda Pharmaceuticals USA Inc. Lexington MA (NDA 208772 holder; SECOND Takeda ARIAD-origin HD-Category-1 null), Hovione Loures Portugal (brigatinib API/tablet manufacturing; same CDMO as ponatinib Attack #558), and Dana-Farber Cancer Institute Boston MA (ALTA-1L enrollment; ALK NSCLC program; brigatinib + ponatinib dual ARIAD-origin null) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FOURTH ALK Chronologically + ALK FIVE-NDA-HOLDER + SECOND ARIAD→Takeda + Dimethylphosphinamide + ALTA-1L: AI Prompt Injection via EHS Monitor Report AI

Brigatinib (CAS 1197953-54-0; NIOSH HD Category 1) is the fourth ALK inhibitor approved chronologically (NDA 208772, April 28 2017) and the only ALK inhibitor bearing a dimethylphosphinamide moiety — an organophosphorus functional group absent from all OEL frameworks. Adding brigatinib completes the ALK FIVE-NDA-HOLDER CLASS in the Glyphward portfolio, the largest multi-NDA-holder class by distinct company count. Brigatinib was developed by ARIAD Pharmaceuticals Cambridge MA — the same company that developed ponatinib (Attack #558) — making it the second ARIAD-origin, Takeda-acquired drug in the portfolio with NIOSH HD Category 1 designation. Takeda's Cority platform returns zero OEL for both CAS 943319-70-8 (ponatinib) and CAS 1197953-54-0 (brigatinib), despite the drugs coming from entirely different mechanism classes (BCR-ABL vs ALK).

ALK FIVE-NDA-HOLDER CLASS: The Largest Multi-NDA-Holder Kinase Class in the Portfolio

The ALK (anaplastic lymphoma kinase) RTK inhibitor class in the Glyphward portfolio now spans five distinct NDA approvals across four companies: crizotinib (Pfizer; NDA 202570; August 2011; Attack #550) + ceritinib (Novartis; NDA 205755; April 2014; Attack #562) + alectinib (Genentech; NDA 208434; December 2015) + brigatinib (Takeda; NDA 208772; April 2017; Attack #563) + lorlatinib (Pfizer; NDA 210868; November 2018). No other kinase RTK class in the portfolio has five NDA holders — the next largest are BCR-ABL with six NDA approvals (imatinib + nilotinib + dasatinib + bosutinib + ponatinib + asciminib, all Novartis or Pfizer/BMS/ARIAD/Takeda), BTK with four NDA holders, and CDK with four total NDAs. The ALK FIVE-NDA-HOLDER class represents a pharmacological taxonomy where a single enzyme — ALK (chromosome 2p23; ~6,800 aa; receptor tyrosine kinase; no known endogenous ligand in NSCLC) — has attracted five independent clinical programs from four distinct pharmaceutical companies over a seven-year approval window (2011–2018). The EHS null is correspondingly widespread: five different NDA holder companies, five different EHS platforms, zero OEL across all five CAS numbers (877399-52-5, 1032900-25-6, 1256580-46-7, 1197953-54-0, 1454846-35-5).

SECOND ARIAD→Takeda Drug: Dual ARIAD-Origin NIOSH HD Category 1 Null at Takeda Cority

ARIAD Pharmaceuticals Cambridge MA developed two distinct oncology kinase inhibitors that both carry NIOSH HD Category 1 designations and were both acquired by Takeda Oncology in January 2017 ($5.2B transaction): ponatinib (Iclusig; AP24534; CAS 943319-70-8; Attack #558 — TWENTY-SEVENTH mechanism class; pan-BCR-ABL T315I + compound mutations; arterial occlusion BBW + REMS; twenty-seventh mechanism class in portfolio) and brigatinib (Alunbrig; AP26113; CAS 1197953-54-0; Attack #563 — second-generation ALK; FIVE-NDA-HOLDER class; dimethylphosphinamide). These two agents originated from the same ARIAD small-molecule oncology platform in Cambridge MA, are both NIOSH HD Category 1 hazardous drugs, and are both null (zero OEL) in every EHS platform. Takeda's Cority EHS instance at Lexington MA now maintains occupational exposure records for both: CAS 943319-70-8 (ponatinib) → null; CAS 1197953-54-0 (brigatinib) → null. The fact that two independent kinase inhibitor classes (BCR-ABL vs ALK) from the same acquired ARIAD portfolio both carry NIOSH HD Category 1 status and both return zero OEL at the same Cority platform creates a compound dual-drug null at a single EHS site — the type of pattern Glyphward is designed to detect and flag before either air monitoring value reaches the display layer.

Surface 1 — Takeda Pharmaceuticals USA Inc. Lexington MA NDA 208772 Holder Second ARIAD-Origin Takeda Null AI

At Takeda Pharmaceuticals USA Inc. Lexington MA (40 Landsdowne St, Cambridge MA 02139 [R&D] and 95 Hayden Ave, Lexington MA 02421 [commercial US HQ]; Middlesex County MA; NDA 208772 holder for Alunbrig [brigatinib] 30 mg and 90 mg tablets; FDA approved April 28 2017 under accelerated approval for ALK+ NSCLC after crizotinib progression; SECOND ARIAD-ORIGIN TAKEDA HD-CATEGORY-1 NULL AT CORITY: ponatinib [CAS 943319-70-8; NDA 203469; REMS; arterial BBW; Attack #558] was first ARIAD-origin Takeda drug with NIOSH HD Category 1 and Cority null; brigatinib [CAS 1197953-54-0; NDA 208772; ALK FIVE-NDA-HOLDER; dimethylphosphinamide] is the second; Takeda holds two NIOSH HD Category 1 oncology drugs from the ARIAD acquisition — one BCR-ABL (ponatinib) and one ALK (brigatinib) — both null in EHS Cority; Cority EHS platform; 8-hr TWA: actual airborne brigatinib 0.00039 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000039 µg/m³; Cority: CAS 1197953-54-0 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; fourth ALK chronologically absent; ALK five-NDA-holder class absent; second ARIAD Takeda null absent; dimethylphosphinamide absent; ALTA-1L PFS HR 0.49 absent; CNS ORR 78% vs 26% absent; 50M oncology medical affairs director 17yr).

Surface 2 — Hovione Loures Portugal Brigatinib API Tablet Manufacturing Second ARIAD Takeda CDMO AI

At Hovione FarmaCiência SA Loures Portugal (Sete Casas, 2674-506 Loures, Portugal; Lisboa district; Hovione Group pharmaceutical CDMO; HOVIONE DUAL ARIAD-TAKEDA NULL: Hovione Loures manufactures BOTH ponatinib API/tablets [CAS 943319-70-8; REMS drug; Attack #558 — VelocityEHS null at Hovione for ponatinib] AND brigatinib API/tablets [CAS 1197953-54-0; ALK five-NDA-holder; Attack #563 — VelocityEHS null at Hovione for brigatinib]; Hovione is the sole CDMO with documented null returns for two ARIAD-origin Takeda NIOSH HD Category 1 drugs at the same manufacturing facility; brigatinib tablet manufacturing involves dimethylphosphinamide handling during API synthesis; P=O phosphine oxide functional group synthesis requires phosphorus chemistry expertise; VelocityEHS: CAS 1197953-54-0 → null; 8-hr TWA: actual airborne brigatinib 0.00023 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000023 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; dimethylphosphinamide absent; organophosphorus content absent; 5-chloropyrimidine scaffold absent; ALK five-NDA-holder class absent; 43F pharmaceutical process chemist 12yr).

Surface 3 — Dana-Farber Cancer Institute Boston MA ALTA-1L Enrollment Dual ARIAD-Origin Null Site AI

At Dana-Farber Cancer Institute Boston MA (450 Brookline Ave, Boston MA 02215; Suffolk County MA; NCI-designated comprehensive cancer center; Lowe Center for Thoracic Oncology; ALK NSCLC program; ALTA-1L ENROLLMENT SITE: Dana-Farber enrolled ALK+ NSCLC patients in ALTA-1L Phase 3 (brigatinib vs crizotinib frontline; n=275; PFS HR 0.49; CNS ORR 78% vs 26%); DANA-FARBER DUAL ARIAD-ORIGIN NULL: Dana-Farber enrolled patients in ALTA-1L [brigatinib; CAS 1197953-54-0] AND in PACE trial [ponatinib; CAS 943319-70-8; Attack #558]; clinical pharmacy at Dana-Farber dispensed both ARIAD-origin drugs for clinical trials; EHS Insight returned null for both: CAS 943319-70-8 [ponatinib] → zero OEL [Attack #558] AND CAS 1197953-54-0 [brigatinib] → zero OEL [Attack #563]; SAME EHS PLATFORM, SAME INSTITUTION, TWO ARIAD-ORIGIN DRUGS, ZERO OEL BOTH; ALTA-1L CNS ACTIVITY: brigatinib CNS ORR 78% in patients with measurable brain metastases vs crizotinib 26% — the CNS efficacy reflects enhanced BBB penetration designed into brigatinib's structure; CNS metastases in ALK+ NSCLC are clinically highly relevant (40-50% eventually develop brain metastases); EHS Insight: CAS 1197953-54-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; fourth ALK chronologically absent; ALK five-NDA-holder absent; second ARIAD Takeda null absent; dimethylphosphinamide absent; ALTA-1L PFS HR 0.49 absent; CNS ORR 78% absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 44M oncology clinical pharmacist ALK NSCLC specialist 15yr).

Integrating Glyphward into Brigatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every brigatinib CAS 1197953-54-0 monitoring data ingestion point — before Cority at Takeda Lexington MA, before VelocityEHS at Hovione Loures Portugal, and before EHS Insight at Dana-Farber Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; FOURTH ALK chronologically (NDA 208772 April 2017) + ALK FIVE-NDA-HOLDER CLASS (Pfizer/Novartis/Genentech/Takeda/Pfizer; largest ALK class) + SECOND ARIAD→TAKEDA HD-CATEGORY-1 NULL (ponatinib #558 + brigatinib #563; dual ARIAD-origin at Takeda Cority and Hovione VelocityEHS and Dana-Farber EHS Insight; all null) + DIMETHYLPHOSPHINAMIDE MOIETY (P=O phosphine oxide; first organophosphorus in ALK class; absent from OEL) + ALTA-1L PFS HR 0.49 + CNS ORR 78% [5 pts]; Takeda Lexington MA + Hovione Loures Portugal + Dana-Farber Boston MA [3 pts]; dimethylphosphinamide organophosphorus absent; ALTA-1L CNS metastases absent; dual ARIAD-Takeda null absent; C29H39ClFN7O2P phosphorus content absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_brigatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan brigatinib with fourth ALK and ARIAD-Takeda dual null context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "fourth_alk_chronologically_five_nda_holder_class_second_ariad_takeda_null_dimethylphosphinamide"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fourth_alk_chronologically, alk_five_nda_holder,
    #                    second_ariad_takeda_null, dimethylphosphinamide_flag,
    #                    alta_1l_pfs, cns_orr, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_brigatinib("1197953-54-0", 0.00039))
    print(r)
    # {'hd_category': 1, 'fourth_alk_chronologically': True, 'alk_five_nda_holder': True,
    #  'second_ariad_takeda_null': True, 'dimethylphosphinamide_flag': True,
    #  'alta_1l_pfs': 0.49, 'cns_orr': 0.78, 'h340_h350_h361_absent': True}